Skip to content

dianosic vs UCB

dianosic logo

dianosic

"Smartly designed for you"

13 employees · est. 2017 · Strasbourg, France

VS
UCB logo

UCB

We’re #TeamUCB, a global biopharmaceutical company. 💙 Inspired by patients 🔬 Driven by science

15278 employees · est. 1928 · Brussels, Belgium

UCB is the older company (2017 vs 1928); UCB is the larger of the two.

Side-by-Side Comparison

dianosic UCB
Founded
2017 1928 older
Headquarters
Strasbourg, France Brussels, Belgium
Employees
13 15278 larger
Industry
Biotechnology, Medical Devices, Pharmaceutical Biotechnology, Health Care, Pharmaceutical
Funding Stage
Seed IPO
Total Funding
$6.20M $194.50M
Funding Rounds
2 5
Services
Development of Transformative Intranasal Solutions, ARIS Platform for Chronic Rhinitis and Rhinosinusitis, Non-Surgical Patient Adherence Solutions, Intranasal Drug Delivery to CNS Personalized patient support, Clinical studies, Drug development and innovation, Healthcare professional collaboration, Scientific publications
Target Customers
Patients with Chronic Rhinitis, Patients with Chronic Rhinosinusitis, Healthcare Professionals, Medical Researchers Patients with neurological disorders, Patients with autoimmune diseases, Healthcare professionals, Women of childbearing age
Taxonomy
Drug Delivery SolutionsChronic Disease ManagementRespiratory DiseasesCentral Nervous System DiseasesPatient AdherenceMedical Compliance Solutions +8 Biopharmaceutical CompanyPatient-centered SolutionsCentral Nervous SystemImmunological ConditionsInnovative HealthcareClinical Outcomes +9
Website
dianosic.com ucb.com
dianosic logo

About dianosic

Dianosic, founded in 2017, operates at the intersection of Biotechnology, Medical Devices, and Pharmaceutical industries. Headquartered in France, the company is embroiled in revolutionizing patient adherence to medication through its innovative sustained intranasal drug delivery solutions, targetin...

UCB logo

About UCB

UCB is a seasoned player in the biopharmaceutical industry, having been established in 1928. Headquartered in Belgium, this global company is dedicated to creating innovative solutions for those living with severe central nervous system and immunological conditions. With the slogan "We’re #TeamUCB,...

Also comparing in this category

Comparing more than these two?

Get dianosic, UCB and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does dianosic compare?

A PDF of dianosic and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

dianosic was founded in 2017, based in Strasbourg, France, with 13 employees. Dianosic, founded in 2017, operates at the intersection of Biotechnology, Medical Devices, and Pharmaceutical industries. Headquartered in France, the company is embroiled in revolutionizing patient a. UCB was founded in 1928, based in Brussels, Belgium, with 15,278 employees. UCB is a seasoned player in the biopharmaceutical industry, having been established in 1928. Headquartered in Belgium, this global company is dedicated to creating innovative solutions for those livin.
dianosic has raised $6.20M and UCB $194.50M. Latest stage: dianosic Seed, UCB IPO.
Both work in Biotechnology and Pharmaceutical.

Compare dianosic with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at dianosic on 7 Jun 2025, and UCB on 23 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout